Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer-Reference-Cited by-同舟云学术

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Published:2022-03 Issue:3 Volume:164 Page:505-513
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Colombo Nicoletta,Tomao Federica,Benedetti Panici Pierluigi,Nicoletto Maria Ornella,Tognon Germana,Bologna Alessandra,Lissoni Andrea Alberto,DeCensi Andrea,Lapresa Mariateresa,Mancari Rosanna,Palaia Innocenza,Tasca Giulia,Tettamanzi Francesca,Alvisi Maria Francesca,Rulli Eliana,Poli Davide,Carlucci Luciano,Torri Valter,Fossati Roldano,Biagioli Elena

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference18 articles.

1. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease;Colombo;Int. J. Gynecol. Cancer,2019

2. Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies;Tomao;Expert. Opin. Pharmacother.,2017

3. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial;Pujade-Lauraine;J. Clin. Oncol.,2014

4. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation;Kaufman;J. Clin. Oncol.,2015

5. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study;Liu;Lancet Oncol.,2014

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments;Current Opinion in Oncology;2024-08-23

2. Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review;Future Oncology;2024-08-12

3. Targeted therapy in high grade serous ovarian Cancer: A literature review;Gynecologic Oncology Reports;2024-08

4. A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib;Gynecologic Oncology;2024-08

5. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial;International Journal of Gynecologic Cancer;2024-05-09